We are committed to developing breakthrough precision medicines for common diseases with large unmet medical needs.
Over the past 20 years, significant advances in human genetics and in the understanding of the biological processes underpinning disease have opened the door to a multitude of new potential therapeutic targets, which we believe presents a unique opportunity for a new approach to precision medicine. Based on insights from our Compass platform, which leverages variant functionalizaton, we design precision medicines that take into account the genetic drivers of disease.
Our commitment to Kidney Disease
Maze Therapeutics is developing medicines designed to imitate the effects of naturally occurring, protective genetic variants and help halt the progression and potentially reverse the effects of kidney disease. Our most advanced program is being evaluated for the treatment of APOL1-mediated kidney disease (AMKD). Our second program targeting SLC6A19 is in development for both chronic kidney disease (CKD), and phenylketonuria (PKU). Learn more about our pipeline here.
